Scleroderma: From pathophysiology to novel therapeutic approaches

Experimental Dermatology

Volumn 19, Issue 5, 2010, Pages 393-400

  Hunzelmann, Nicolas ^a   Krieg, Thomas ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Connective tissue; Fibrosis; Growth factor; Hypoxia

Indexed keywords

BOSENTAN; CONNECTIVE TISSUE GROWTH FACTOR; GROWTH FACTOR; IMATINIB; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SILDENAFIL; TRANSFORMING GROWTH FACTOR BETA;

B LYMPHOCYTE; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; DISEASE COURSE; DRUG MECHANISM; FIBROSIS; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOPATHOGENESIS; MYELOFIBROSIS; NONHUMAN; PATHOPHYSIOLOGY; PHOTOTHERAPY; PROTEIN FUNCTION; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; REVIEW; SCLERODERMA; SIGNAL TRANSDUCTION; SKIN FIBROSIS; SKIN ULCER; SYSTEMIC SCLEROSIS; ULTRAVIOLET A RADIATION;

FIBROSIS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; SCLERODERMA, SYSTEMIC; VASCULAR DISEASES;

EID: 77953142653     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2010.01082.x     Document Type: Review

References (115)

1. White B, Bauer E A, Goldsmith L A. Guidelines for clinical trials in systemic sclerosis (scleroderma). I. disease modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic sclerosis. Arthritis Rheum 1995, 38:351-360.
2. Matucci-Cerinic M, Steen V D, Furst D E, Seibold J R. Clinical trials in systemic sclerosis: lessons learned and outcomes. Arthritis Res Ther 2007, 9:S7.
3. Walker U A, Tyndall A, Czirják L. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007, 66:754-763.
4. Hunzelmann N, Genth E, Krieg T. The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology (Oxford) 2008, 47:1185-1192.
5. Denton C P, Black C M. Scleroderma - clinical and pathological advances. Best Pract Res Clin Rheumatol 2004, 18:271-290.
6. Avouac J, Kowal-Bielecka O, Landewe R. European League Against Rheumatism (EULAR) Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of systematic literature research. Ann Rheum Dis 2009, 68:629-634.
7. Kowal-Bielecka O, Landewé R, Avouac J. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009, 68:620-628.
8. Ntoumazios S K, Voulgari P V, Potsis K, Koutis E, Tsifetaki N, Assimakopoulos D A. Esophageal involvement in scleroderma: gastroesophageal reflux, the common problem. Semin Arthritis Rheum 2006, 36:173-181.
9. Hunzelmann N, Moinzadeh P, Genth E. High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy. Arthritis Res Ther 2009, 11:R30.
10. Tashkin D P, Elashoff R, Clements P J. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006, 354:2655-2666.
11. Steen V D, Medsger T A. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007, 66:940-944.
12. Ferri C, Valentini G, Cozzi F. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 2002, 81:139-153.
13. Al-Dhaher F F, Pope J E, Ouimet J M. Determinants of Morbidity and Mortality of Systemic Sclerosis in Canada. Semin Arthritis Rheum 2010, 39:269-277.
14. Ioannidis J P, Vlachoyiannopoulos P G, Haidich A B. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 2005, 118:2-10.
15. Khanna D, Lovell D J, Giannini E. Scleroderma Clinical Trials Consortium co-authors. Development of a provisional core set of response measures for clinical trials of systemic sclerosis. Ann Rheum Dis 2008, 67:703-709.
16. Prescott R J, Freemont A, Jones C. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 1992, 166:255-263.
17. Maricq H, LeRoy E, Dangelo W. Diagnostic potential of in vivo capillary microscopy in scleroderma and related disorders. Arthritis Rheum 1980, 23:83-189.
18. Sgonc R, Gruschwitz M, Dietrich H. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 1996, 98:785-792.
19. Kahaleh M, Fan P S. Mechanism of serum mediated endothelial injury in scleroderma: identification of a granular enzyme in scleroderma skin and sera. Clin Immunol Immunopathol 1997, 83:32-40.
20. Hebbar M, Peyrat J P, Hornez L, Hatron P Y, Hachulla E, Devulder B. Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. Arthritis Rheum 2000, 43:889-893.
21. Lunardi C. Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nat Med 2000, 6:1183-1186.
22. Lunardi C, Dolcino M, Peterlana D. Antibodies against human cytomegalovirus in the pathogenesis of systemic sclerosis: a gene array approach. PLoS Med 2006, 3:e2.
23. Fleming J N, Nash R A, McLeod D O. Capillary regeneration in scleroderma: stem cell therapy reverses phenotype? PLoS ONE 2008, 16:3.
24. Beyer C, Schett G, Gay S, Distler O, Distler J H. Hypoxia in the pathogenesis of systemic sclerosis. Arthritis Res Ther 2009, 11:220.
25. Kuwana M, Okazaki Y, Yasuoka H, Kawakami Y, Ikeda Y. Defective vasculogenesis in systemic sclerosis. Lancet 2004, 364:603-610.
26. Kuryliszyn-Moskal A, Klimiuk P A, Sierakowski S. Soluble adhesion molecules (sVCAM-1, sE-selectin), vascular endothelial growth factor (VEGF) and endothelin-1 in patients with systemic sclerosis: relationship to organ systemic involvement. Clin Rheumatol 2005, 24:111-116.
27. Allanore Y, Batteux F, Avouac J, Assous N, Weill B, Kahan A. Levels of circulating endothelial progenitor cells in systemic sclerosis. Clin Exp Rheumatol 2007, 25:60-66.
28. Distler J H, Allanore Y, Avouac J. EULAR Scleroderma Trials and Research group statement and recommendations on endothelial precursor cells. Ann Rheum Dis 2009, 68:163-168.
29. Avouac J, Wipff J, Goldman O. Angiogenesis in systemic sclerosis: impaired expression of vascular endothelial growth factor receptor 1 in endothelial progenitor-derived cells under hypoxic conditions. Arthritis Rheum 2008, 58:3550-3561.
30. Distler O, Del Rosso A, Giacomelli R. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 2002, 4:R11.
31. Distler O, Distler J H, Scheid A. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 2004, 9:95.
32. Davies C A, Jeziorska M, Freemont A J, Herrick A L. The differential expression of VEGF, VEGFR-2, and GLUT-1 proteins in disease subtypes of systemic sclerosis. Hum Pathol 2006, 37:190-197.
33. Brinckmann J, Kim S, Wu J. Interleukin 4 and prolonged hypoxia induce a higher gene expression of lysyl hydroxylase 2 and an altered cross-link pattern: important pathogenetic steps in early and late stage of systemic scleroderma? Matrix Biol 2005, 24:459-468.
34. Distler J H, Jüngel A, Pileckyte M. Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis. Arthritis Rheum 2007, 56:4203-4215.
35. Hong K H, Yoo S A, Kang S S, Choi J J, Kim W U, Cho C S. Hypoxia induces expression of connective tissue growth factor in scleroderma skin fibroblasts. Clin Exp Immunol 2006, 146:362-370.
36. Higgins D F, Kimura K, Bernhardt W M. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Invest 2007, 117:3810-3820.
37. Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res 2009, 19:156-172.
38. Scorza R, Caronni M, Mascagni B. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study. Clin Exp Rheumatol 2001, 19:503-508.
39. Sunderkötter C, Herrgott I, Brückner C. Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors. Br J Dermatol 2009, 160:835-843.
40. King T E, Behr J, Brown K K. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008, 1:177.
41. Zuo F, Kaminski N, Eugui E. Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc Natl Acad Sci USA 2002, 99:6292-6297.
42. Terao M, Murota H, Kitaba S, Katayama I. Tumor necrosis factor-alpha processing inhibitor-1 inhibits skin fibrosis in a bleomycin-induced murine model of scleroderma. Exp Dermatol 2010, 18:38-43.
43. Buhling F, Rocken C, Brasch F. Pivotal role of cathepsin K in lung fibrosis. Am J Pathol 2004, 164:2203-2216.
44. van der Slot A J, Zuurmond A M, Bardoel A F. Identification of PLOD2 as telopeptide lysyl hydroxylase, an important enzyme in fibrosis. J Biol Chem 2003, 278:40967-40972.
45. Hunzelmann N, Risteli J, Risteli L, Sacher C, Black C M, Krieg T. Increased circulating concentrations of the type I collagen specific degradation product ICTP in systemic sclerosis reflect the extent of skin involvement: a new serum marker for clinical severity in SSc patients. Br J Dermatol 1998, 139:1020-1025.
46. Allanore Y, Borderie D, Lemaréchal H, Cherruau B, Ekindjian O G, Kahan A. Correlation of serum collagen I carboxyterminal telopeptide concentrations with cutaneous and pulmonary involvement in systemic sclerosis. J Rheumatol 2003, 30:68-73.
47. Kötter I, Henes J, Koch S, Kanz L, Hunzelmann N. Autologous peripheral blood stem cell transplantation for systemic sclerosis - C-terminal collagen telopeptide serum levels as a biomarker for reduction of fibrosis and clinical improvement. Ann Rheum Dis 2007, 66(Suppl. II):213.
48. Gardner H, Shearstone J R, Bandaru R. Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts. Arthritis Rheum 2006, 54:1961-1973.
49. Milano A, Pendergrass S A, Sargent J L. Molecular Subsets in the Gene Expression Signatures of Scleroderma Skin. PLoS ONE 2008, 3:e2696.
50. Vancheeswaran R, Azam A, Black C, Dashwood M R. Localization of endothelin-1 and its binding sites in scleroderma skin. J Rheumatol 2004, 21:1268-1276.
51. Xu S W, Howat S L, Renzoni E A. Endothelin-1 induces expression of matrix-associated genes in lung fibroblasts through MEK/ERK. J Biol Chem 2004, 28:279.
52. Horstmeyer A, Licht C, Scherr G, Eckes G, Krieg T. Signalling and regulation of collagen I synthesis by ET-1 and TGF-beta 1. FEBS J 2005, 272:6297-6309.
53. Kokot A, Sindrilaru A, Schiller M. alpha-melanocyte-stimulating hormone suppresses bleomycin-induced collagen synthesis and reduces tissue fibrosis in a mouse model of scleroderma: melanocortin peptides as a novel treatment strategy for scleroderma? Arthritis Rheum 2009, 60:592-603.
54. Iwano M, Plieth D, Danoff T M, Xue C, Okada H, Nielson E G. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 2002, 110:341-350.
55. Zeisberg E M, Tarnavaski O, Zeisberg M. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 2007, 13:952-961.
56. Simonson M S. Phenotypic transitions and fibrosis in diabetic nephropathy. Kidney Int 2007, 71:846-854.
57. Bellini A, Mattoli S. The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses. Lab Invest 2007, 87:858-870.
58. Wahl S M. Transforming growth factor-beta: innately bipolar. Curr Opin Immunol 2007, 19:55-62.
59. Leask A, Abraham D J. TGF-beta signaling and the fibrotic response. FASEB J 2004, 18:816-827.
60. Trojanowska M, Varga J. Molecular pathways as novel therapeutic targets in systemic sclerosis. Curr Opin Rheumatol 2007, 19:568-573.
61. Ihn H, Yamane K, Kubo M, Tamaki K. Blockade of endogenous transforming growth factor beta signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor beta receptors. Arthritis Rheum 2001, 44:474-480.
62. Kawakami T, Ihn H, Xu W, Smith E, LeRoy C, Trojanowska M. Increased expression of TGF-beta receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-beta signaling to scleroderma phenotype. J Invest Dermatol 1998, 110:47-51.
63. Isaka Y, Brees D K, Ikegaya K. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat Med 1996, 2:418-423.
64. McCormick L L, Zhang Y, Tootell E, Gilliam A C. Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol 1999, 163:5693-5699.
65. Santiago B, Gutierrez-Canas I, Dotor J. Topical application of a peptide inhibitor of transforming growth factor-beta1 ameliorates bleomycin-induced skin fibrosis. J Invest Dermatol 2005, 125:450-455.
66. Hermida N, López B, González A. A synthetic peptide from transforming growth factor-beta1 type III receptor prevents myocardial fibrosis in spontaneously hypertensive rats. Cardiovasc Res 2009, 15:81.
67. Lakos G, Takagawa S, Chen S J. Targeted disruption of TGF-beta/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma. Am J Pathol 2004, 165:203-217.
68. Mead A L, Wong T T, Cordeiro M F, Anderson I K, Khaw P T. Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Invest Ophthalmol Vis Sci 2003, 44:3394-3401.
69. Khaw P, Grehn F. A phase III study of subconjunctival human anti-transforming growth factor beta (2) monoclonal antibody (CAT-152) to prevent scarring after first-time trabeculectomy. Ophthalmology 2007, 114:1822-1830.
70. Denton C P, Merkel P A, Furst D E. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 2007, 56:323-333.
71. Heldin C-H, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999, 79:1283-1316.
72. Rosenkranz S, Kazlauskas A. Evidence for distinct signaling properties and biological responses induced by the PDGF receptor α and β subtypes. Growth Factors 1999, 16:201-216.
73. Vantler M, Caglayan E, Zimmermann W H, Bäumer A T, Rosenkranz S. Systematic evaluation of anti-apoptotic growth factor signaling in vascular smooth muscle cells: only phosphatidylinositol 3′-kinase is important. J Biol Chem 2005, 280:14168-14176.
74. Schermuly R T, Dony E, Ghofrani H A. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005, 115:2811-2821.
75. Olson L E, Soriano P. Increased PDGFRα Activation Disrupts Connective Tissue Development and Drives Systemic Fibrosis. Dev Cell 2009, 16:303-313.
76. Baroni S S, Santillo M, Bevilacqua F. Stimulatory Autoantibodies to the PDGF Receptor in Systemic Sclerosis. N Engl J Med 2006, 354:2667-2676.
77. Svegliati S, Olivieri A, Campelli N. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood 2007, 1:110.
78. Dragun D, Distler J H, Riemekasten G, Distler O. Stimulatory autoantibodies to platelet-derived growth factor receptors in systemic sclerosis: what functional autoimmunity could learn from receptor biology. Arthritis Rheum 2009, 60:907-911.
79. Perbal B. The CCN family of genes: a brief history. Mol Pathol 2001, 54:103-104.
80. Frazier K, Williams S, Kothapalli D, Klapper H, Grotendorst G R. Stimulation of fibroblast cell growth, matrix production, and granulation tissue formation by connective tissue growth factor. J Invest Dermatol 1996, 107:404-411.
81. Igarashi A, Nashiro K, Kikuchi K. Connective tissue growth factor gene expression in tissue sections from localized scleroderma, keloid, and other fibrotic skin disorders. J Invest Dermatol 1996, 106:729-733.
82. Denton C P, Abraham D J. Transforming growth factor-beta and connective tissue growth factor: key cytokines in scleroderma pathogenesis. Curr Opin Rheumatol 2001, 13:505-511.
83. Wynn T A. Cellular and molecular mechanisms of fibrosis. J Pathol 2008, 214:199-210.
84. Gabrielli A, Avvedimento E V, Krieg T. Scleroderma. N Engl J Med 2009, 360:57-71.
85. Ghofrani H A, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005, 29:353.
86. Buesche G, Ganser A, Schlegelberger B. Marrow fibrosis and its relevance during imatinib treatment of chronic myeloid leukemia. Leukemia 2007, 21:2420-2427.
87. Distler J H, Jüngel A, Huber L C. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007, 56:311-322.
88. Akhmetshina A, Dees C, Pileckyte M. Dual inhibition of c-abl and PDGF receptor signaling by datatinib and nilotinib for the treatment of dermal fibrosis. FASEB J 2008, 22:2214-2222.
89. Akhmetshina A, Venalis P, Dees C. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of fibrosis. Arthritis Rheum 2009, 60:219-224.
90. Sfikakis P P, Gorgoulis V G, Katsiari C G. Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology (Oxford) 2008, 47:735-737.
91. Distler J H, Manger B, Spriewald B M, Schett G, Distler O. Treatment of pulmonary fibrosis for twenty weeks with imatinib mesylate in a patient with mixed connective tissue disease. Arthritis Rheum 2008, 58:2538-2542.
92. Magro L, Mohty M, Catteau B. Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease. Blood 2009, 16:114.
93. Furst D E, Clements P J. D-penicillamine is not an effective treatment in systemic sclerosis. Scand J Rheumatol 2001, 30:189-191.
94. Pope J, Bellamy N, Seibold J. A randomized controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001, 44:1351-1358.
95. Klose A, Wilbrand-Hennes A, Brinckmann J, Hunzelmann N. Alternate trafficking of cathepsin L in dermal fibroblasts induced by UVA radiation. Exp Dermatol 2010, 10.1111/j.1600-0625.2009.01014.x, DOI, (Epub ahead of print)
96. Brinckmann J, Neess C M, Gaber Y. Different patterns of collagen cross-links in two sclerotic skin diseases: lipodermatosclerosis and circumscribed scleroderma. J Invest Dermatol 2001, 117:269-273.
97. Sunderkötter C, Kuhn A, Hunzelmann N, Beissert S. Phototherapy: a promising treatment option for skin sclerosis in scleroderma? Rheumatology 2006, 45:iii52-iii54.
98. Arin M J, Hunzelmann N. Anti-B- cell-directed immunotherapy (rituximab) in the treatment of refractory pemphigus--an update. Eur J Dermatol 2005, 15:224-230.
99. Kim D, Peck A, Santer D. Induction of interferon-a by scleroderma sera containing autoantibodies to topoisomerase I. Arthritis Rheum 2008, 58:2163-2173.
100. Dragun D, Müller D N, Bräsen J H. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005, 10:352.
101. Zhou C C, Zhang Y, Irani R A. Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat Med 2008, 14:855-862.
102. Xia Y, Kellems R E. Is preeclampsia an autoimmune disease? Clin Immunol 2009, 133:1-12.
103. Matsushita T, Fujimoto M, Hasegawa M. Elevated serum APRIL levels in patients with systemic sclerosis: distinct profiles of systemic sclerosis categorized by APRIL and BAFF. J Rheumatol 2007, 34:2056-2062.
104. Lafyatis R, O'Hara C, Feghali-Bostwick C A, Matteson E. B cell infiltration in systemic sclerosis-associated interstitial lung disease. Arthritis Rheum 2007, 56:3167-3168.
105. Saito E, Fujimoto M, Hasegawa M. CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest 2002, 109:1453-1462.
106. Hasegawa M, Hamaguchi Y, Yanaba K. B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol 2006, 169:954-966.
107. Fabri M, Hunzelmann N, Krieg T, Rubbert A. Discordant response to rituximab in a systemic sclerosis patient with associated myositis. J Am Acad Dermatol 2008, 58(5 Suppl. 1):127-128.
108. Lafyatis R, Kissin E, York M. B Cell Depletion With Rituximab in Patients With Diffuse Cutaneous Systemic Sclerosis. Arthritis Rheum 2009, 60:578-583.
109. Smith V, Van Praet J T, Vandooren B R. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis 2010, 69:193-197.
110. Hoyer B F, Mumtaz I M, Yoshida T, Hiepe F, Radbruch A. How to cope with pathogenic long-lived plasma cells in autoimmune diseases. Ann Rheum Dis 2008, 67(Suppl. 3):iii87-iii89.
111. Tyndall A, Furst D E. Adult stem cell treatment of scleroderma. Curr Opin Rheumatol 2007, 19:604-610.
112. Binks M, Passweg J R, Furst D. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis 2001, 60:577-584.
113. Farge D, Marolleau J P, Zohar S. Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I-II study. Br J Haematol 2002, 119:726-739.
114. Vonk M C, Marjanovic Z, van den Hoogen F H. Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis. Ann Rheum Dis 2008, 67:98-104.
115. Nash R A, McSweeney P A, Nelson J L. Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis. Arthritis Rheum 2006, 54:1982-1986.